Investor Presentation Q1 2022
10
Investor presentation
First three months of 2022
During the first quarter, weekly prescriptions of WegovyⓇ in the
US exceeded 20,000
TRX count (000s)
48
4 20
40
32
24
24
16
8
0
Jan
2019
Jan
2020
Branded AOM TRX in the US
Jan
2021
44.5
лучш
24.8
10.2
SaxendaⓇ
WegovyⓇ
Branded AOM Market
Each TRX data points represents one week of data
NAO: North America operations, IO: International operations, RHS: Right hand side axis, Rx: Prescriptions
AOM: Anti-Obesity Medications (includes WegovyⓇ, SaxendaⓇ, Qsymia and Contrave),
Source: IQVIA NPA - TRX data, weekly (ending 08 April 2022)
WegovyⓇ in the US
Novo NordiskⓇ
•
•
ONCE-WEEKLY
wegovy®
semaglutide injection 2.4 mg
Commercial formulary access around 80%
The three lowest dose strengths of
WegovyⓇ are currently not available
Contract manufacturer has reinitiated
commercial production
Novo Nordisk expects to make WegovyⓇ
available in the US during second half of
2022
Jan
2022
Apr
2022
.View entire presentation